Transcript Slide 1

Thalidomide-based Regimens:
Rates of VTE* in Previously Treated MM
Treatment
T alone (95% CI)
T+ prednisone
(95% CI)
TC (95% CI)
TD (95% CI)
TDC agents (95% CI)
TDC including
doxorubicin (95% CI)
No prophylaxis
0.4
(0.2–0.8)
(n=706)
0.6
(0.2–1.1)
(n=258)
0.4
(0.01–1.2)
(n=38)
0.8
(0.1–2.1)
(n=321)
0.9
(0.3–1.8)
(n=321)
6.7
(0.5–18.9)
(n=331)
ASA
Warfarin
1-1.25 mg/d
Prophylactic
LMWH
Therapeutic
Doses of
Anticoagulation
NA
NA
0
(0–1.72)
(n=17)
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
0
(0–2.2)
(n=18)
0.4
(0.01–0.9)
(n=37)
NA
NA
NA
NA
2.4
(1.3–4)
(n=102)
3.5
(1.2–6.5)
(n=50)
NA
Lenalidomide-based regimens
*per 100 patient-months
ASA=aspirin; LMWH=low molecular weight heparin; MM=multiple myeloma; T=thalidomide; TC=thalidomide + cytotoxic chemotherapy; TD=thalidomide +
dexamethasone; TDC=thalidomide + dexamethasone + cytotoxic chemotherapy; VTE=venous thromboembolism
1090